E
Ewa Chmielowska
Researcher at Nicolaus Copernicus University in Toruń
Publications - 30
Citations - 2083
Ewa Chmielowska is an academic researcher from Nicolaus Copernicus University in Toruń. The author has contributed to research in topics: Ibrutinib & Bendamustine. The author has an hindex of 8, co-authored 27 publications receiving 1750 citations.
Papers
More filters
Journal ArticleDOI
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
Michael L. Wang,Simon Rule,Peter Martin,Andre Goy,Rebecca Auer,Brad S. Kahl,Brad S. Kahl,Wojciech Jurczak,Ranjana H. Advani,Jorge E. Romaguera,Michael E. Williams,Jacqueline C. Barrientos,Ewa Chmielowska,John Radford,Stephan Stilgenbauer,Martin Dreyling,Wiesław Wiktor Jędrzejczak,Peter Johnson,Stephen E. Spurgeon,Lei Li,Liang Zhang,Kate J. Newberry,Zhishuo Ou,Nancy Cheng,Bingliang Fang,Jesse McGreivy,Fong Clow,Joseph J. Buggy,Betty Y. Chang,Darrin M. Beaupre,Lori Kunkel,Kristie A. Blum +31 more
TL;DR: Ibrutinib shows durable single-agent efficacy in relapsed or refractory mantle-cell lymphoma and is enrolled into two groups: patients who had previously received at least 2 cycles of bortezomib therapy and those who had received less than 2 complete cycles.
Journal ArticleDOI
Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results.
Michael L. Wang,Kristie A. Blum,Peter Martin,Andre Goy,Rebecca Auer,Brad S. Kahl,Wojciech Jurczak,Ranjana H. Advani,Jorge E. Romaguera,Michael E. Williams,Jacqueline C. Barrientos,Ewa Chmielowska,John Radford,Stephan Stilgenbauer,Martin Dreyling,Wiesław Wiktor Jędrzejczak,Peter Johnson,Stephen E. Spurgeon,Liang Zhang,Linda Baher,Mei Cheng,Dana Lee,Darrin M. Beaupre,Simon Rule +23 more
TL;DR: With longer follow-up, ibrutinib continues to demonstrate durable responses and favorable safety in relapsed/refractory MCL and is approved for patients with mantle cell lymphoma who have received one prior therapy.
Journal ArticleDOI
Postibrutinib outcomes in patients with mantle cell lymphoma.
Peter Martin,Kami J. Maddocks,John P. Leonard,Jia Ruan,Andre Goy,Nina D. Wagner-Johnston,Simon Rule,Ranjana H. Advani,David J. Iberri,Tycel Phillips,Stephen E. Spurgeon,Eliana Kozin,Katherine Noto,Zhengming Chen,Wojciech Jurczak,Rebecca Auer,Ewa Chmielowska,Stephan Stilgenbauer,Johannes Bloehdorn,Craig A. Portell,Michael E. Williams,Martin Dreyling,Paul M. Barr,Selina Chen-Kiang,Maurizio DiLiberto,Richard R. Furman,Kristie A. Blum +26 more
TL;DR: A retrospective cohort study of all patients with MCL who experienced disease progression while receiving ibrutinib across 15 international sites, poor clinical outcomes were noted in the majority of patients with primary or secondary ibrUTinib resistance and treatments could not identify treatments that clearly improved outcomes.
Journal ArticleDOI
A randomized, double-blind, placebo-controlled phase 2 study of tigatuzumab (CS-1008) in combination with carboplatin/paclitaxel in patients with chemotherapy-naïve metastatic/unresectable non-small cell lung cancer.
Martin Reck,Maciej Krzakowski,Ewa Chmielowska,Martin Sebastian,Dietrich Hadler,Tara Fox,Qiang Wang,Jon Greenberg,Robert A. Beckman,Joachim von Pawel +9 more
TL;DR: Tigatuzumab was well tolerated but did not improve efficacy of carboplatin/paclitaxel in systemic therapy-naïve, unselected advanced NSCLC patients.
Journal ArticleDOI
Single-Agent Ibrutinib Demonstrates Safety and Durability of Response at 2 Years Follow-up in Patients with Relapsed or Refractory Mantle Cell Lymphoma: Updated Results of an International, Multicenter, Open-Label Phase 2 Study
Michael Wang,Simon Rule,Peter Martin,Andre Goy,Rebecca Auer,Brad S. Kahl,Wojciech Jurczak,Ranjana H. Advani,Jorge E. Romaguera,Michael E. Williams,Jacqueline C. Barrientos,Ewa Chmielowska,John Radford,Stephan Stilgenbauer,Martin Dreyling,Wiesław Wiktor Jędrzejczak,Peter Johnson,Stephen E. Spurgeon,Liang Zhang,Linda Baher,Mei Cheng,Darrin M. Beaupre,Kristie A. Blum +22 more
TL;DR: The durability of responses and favorable safety profile of daily oral ibrutinib in relapsed or refractory MCL continued to be demonstrated, and no clinically significant changes were observed in immunoglobulin levels over time.